Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-D16 risk-stratified chemotherapy study in children with Down syndrome and newly diagnosed AML
jRCTs041190047Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2019
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cytarabine, etoposide, tioguanine, cyclophosphamide, vincristine and 1 more in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by Japan Agency for Medical Research and Development. Started Jul 2019; status: active, not recruiting.
02
Drugs
cytarabineetoposidetioguaninecyclophosphamidevincristine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCTs041190047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190047.